These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38653068)

  • 1. Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.
    Cao X; Fan Z; Xu L; Zhao W; Zhang H; Yang Y; Ren Y; Xiao Y; Zhou N; Yin L; Zhou X; Zhu X; Guo D
    Eur J Med Chem; 2024 May; 271():116428. PubMed ID: 38653068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
    Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
    J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
    Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
    Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease.
    Yanda MK; Liu Q; Cebotaru L
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F997-F1004. PubMed ID: 28747357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetics and autosomal dominant polycystic kidney disease.
    Li X
    Biochim Biophys Acta; 2011 Oct; 1812(10):1213-8. PubMed ID: 20970496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.
    Fan LX; Li X; Magenheimer B; Calvet JP; Li X
    Kidney Int; 2012 Jan; 81(1):76-85. PubMed ID: 21900881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
    Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
    Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models.
    Cao Y; Semanchik N; Lee SH; Somlo S; Barbano PE; Coifman R; Sun Z
    Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21819-24. PubMed ID: 19966229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
    Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.